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Background: Small fiber neuropathy (SFN) appears to be relatively common in sarcoidosis
patients. However, there is no golden standard to establish SFN and diagnostic tests for SFN
are not widely available. There is a need for an easy to administer SFN screening instrument
for clinical assessment, research or therapeutic trials. The aim of the present study was to
develop a screening list to identify sarcoidosis patients with SFN in general clinical practice.
Methods: We studied 139 sarcoidosis patients. The first consecutive 84 patients (Group 1)
underwent temperature threshold testing (TTT) and completed an extensive SFN-symptoms-
questionnaire. Based on data from Group 1 and using distribution measures and discriminant
analyses, a screening list for SFN in sarcoidosis consisting of 21 questions was constructed:
the Small Fiber Neuropathy Screening List (SFNSL). Subsequently, this SFNSL was crossvali-
dated in the next 55 consecutive patients (Group 2).
Results: The same cut-off scores as found for Group 1 were appropriate in Group 2. The SFNSL
was found to have high levels of internal consistency (Cronbach’s alpha 0.90) and exploratory
factor analysis showed that it measures only one underlying factor. Convergent validity seems
good.
Conclusion: To assess the presence of SFN in clinical practice the SFNSL, a brief and easy to
administer questionaire, was developed in a sarcoidosis population. The results of the present
study support the idea that SFN is a serious problem in chronic sarcoidosis. Future studies are
needed to establish the broad usefulness of this SFN screening list and expand knowledge on
the psychometric properties.
ª 2010 Elsevier Ltd. All rights reserved.spiratory Medicine, ild care team, Maastricht University Medical Centre, P.O. Box 5600, 6202 AZ
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96 E. Hoitsma et al.Introduction list was constructed (see below). Patients seen afterSarcoidosis is a disseminated granulomatous disease of
unknown origin.1,2 Depending on the organs involved and the
severity of granulomatous inflammation, patients suffer
from a broad range of persistent physical symptoms. Besides
respiratory symptoms such as coughing and dyspnea on
exertion, patients often suffer from systemic non-specific
symptoms such as fatigue, pain and cognitive failure.3e7
Pain is considered to be a reflex response to underlying
somatic pathology. In a previous study we found that many
sarcoidosis patients with peripheral pain appeared to suffer
from small fiber neuropathy (SFN) with involvement of
autonomic nerve fibers.8e10 SFN is a generalised peripheral
neuropathy selectively involving Ad and C fibers. When the
somatic small afferent fibers are affected, symptoms typi-
cally consist of neuropathic pain. Furthermore, autonomic
fibers may be involved, causing autonomic dysfunction.11
Routinely applied nerve conduction tests as well as
tendon reflexes evaluate only large nerve fiber function and
consequently remain normal in isolated SFN. Besides,
symptoms of autonomic dysfunction are not always suffi-
ciently severe to be mentioned spontaneously by the
patient. Furthermore, sarcoidosis patients are generally
seen by physicians, such as internists and pulmonologists,
who may not be familiar with SFN. Therefore, the diagnosis
of SFN can easily be missed. Tests for assessment of small
nerve fibers include temperature threshold testing (TTT),
quantitative sudomotor axon reflex testing (QSART), intra-
epidermal nerve fiber density assessment in skin biopsy and
laser evoked potentials.11,12 These tests are not widely
available, however.
There is a need for adequate means of assessing the
presence of SFN, both for clinical management and also for
guidance of the development of further therapies. Assess-
ment of SFN may also be useful in epidemiological and
pathophysiological studies. The aim of the present study
was to develop a short and easy to administer questionnaire
that screens for the presence of SFN in sarcoidosis patients.
The TTT was used to diagnose SFN.
Materials and methods
Participants
From 2001 to 2004, 139 (82 males and 57 females)
consecutive sarcoidosis patients who visited the outpatient
clinic of the University Hospital Maastricht, a referral
centre for sarcoidosis, participated in the present study.
Patients were diagnosed with sarcoidosis based on consis-
tent clinical features and bronchoalveolar lavage (BAL)
fluid analysis or biopsy results, according to the WASOG
guidelines.1 Informed consent was obtained from all
participating patients. Relevant co-morbidity only included
diabetes mellitus (nZ 7). Glucose tolerance tests were not
performed nor were other causes for SFN tested.
The first consecutive 84 patients seen before August
2003 (49 males and 35 females; mean age 44.2  11.1)
were evaluated with an extensive pilot questionnaire
(Group 1). Based on these data and using distribution
measures and discriminant analyses, a shorter screeningAugust 2003 (Group 2) were used for cross-validation of this
screening list. This group consisted of 55 patients (34 males
and 21 females; mean age 45.5  10.7). Patient charac-
teristics are summarized in Table 1.
Finally, 15 healthy controls (mean age 33.3  9.8;
8 males, 7 females) were evaluated. Healthy controls were
excluded if they had a history of chronic pain, hernia,
diabetes, systemic disease, renal disease or alcohol abuse.
Pilot questionnaire of the Small Fiber Neuropathy
Screening List (SFNSL)
Based on clinical experience and existing neuropathy
questionnaires,13e21 a pilot questionnaire consisting of 93
questions, covering some 30 different complaints, was
constructed. It had three parts: questions in part I (35
questions) concerned presence or absence of complaints;
questions in part II (29 questions) were aimed at the
frequency of complaints; and part III (29 questions) con-
cerned the severity of the complaints. The response scale
for part II ranged from 0 Never to 4 Always and for part III
the scale went from 0 Never to 4 Severe. The patients in
Group 1 who reported pain also completed the Neuropathic
Pain Scale.22
Temperature threshold testing (TTT)
TTT was used to assess function of small calibre sensory
fibers by measuring temperature sensation thresholds. TTT
was done with a Medoc TSA-2001 device (Medoc, Ramat
Yishai, Israel). Thresholds for warm and cold sensation were
determined on the hand and dorsum of the foot on both
sides using the method of levels (MLE) and the method of
limits (MLI) as described previously.10 Normative data
according to Yarnitsky were used.23 Temperature sensation
was considered abnormal if at least on one side both MLE
and MLI testing resulted in Z values exceeding 2.5 (above
the 99th percentile).9
Statistical procedure and construction steps of te
SFNSL
Frequencies were used for the characteristics of the patient
groups. A number of steps were performed using Group 1 to
develop the SFNSL by reducing the number of questions of
the pilot questionnaire. First, missing values were examined
to identify questions with a percentage of missing values
above 10%. Second, remarks from patients concerning the
questionnaire were recorded. Furthermore, three series of
discriminant analyses were performed starting with (i) the
questions fromPart II and (ii) thequestions fromPart III of the
pilot questionnaire, and (iii) the remaining questions from
Part II and III together. The criteria for the discriminant
analyses were the size of the discriminant function, the
percentage predicted in the correct category, and reducing
the number of questions as much as possible. This resulted in
the SFNSL. Subsequently, exploratory factor analysis (prin-
ciple axis factoring) was performed using the scree test
criterion24 to establish the number of underlying factors
measured by the questionnaire and Cronbach’s alpha was
Table 1 Summary of the most relevant characteristics of the studied sarcoidosis population.
Group 1 (n Z 84) Group 2 (n Z 55)
TTT normal TTT abnormal TTT normal TTT abnormal
Number of patients 31 53 19 36
Age (year) 37.3  9.8 47.3  10.7* 38.1  8.9 45.1  9.6
Sex (male/female) 12/19 34/19 9/10 25/11
Diabetes (yes/no) 1/30 2/51 1/18 3/33
Time since diagnosis (year) 2.5  3.9 5.8  8.2* 2.4  2.6 5.9  6.6*
Chest X-ray stage (0/I/II/III/IV) 6/4/6/12/3 8/9/18/13/5 3/2/4/4/6 6/8/12/8/2
Prednison (yes/no) 14/17 20/33 8/11 18/19
SFNSL score < 11 21 0 14 0
SFNSL score 11e48 10 37* 5 24*
SFNSL score > 48 0 16 0 12
TTT: temperature threshold testing. SFNSL: Small Fiber Neuropathy Screening List. Data are expressed as absolute numbers and, if
appropriate, mean  standard deviation. No statistical differences were found between group 1 and 2.*p < 0.05 between the subgroups
with a normal TTT or an abnormal TTT.
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a criterion of 0.70e0.80 to indicate adequate internal
consistency.25 In addition, Pearson correlations and t-tests
were performed between the SFNSL and the neuropathic
pain scale (NPS), depending on the questions of the latter
questionnaire, to provide some preliminary information on
construct or convergent validity. It is usually accepted that
correlations above 0.40 indicate acceptable convergent
validity.26 The SFNSL was than completed by Group 2. The
percentage of missing values was checked. Again, explor-
atory factor analysis (principle axis factoring)was performed
and internal consistency was examined. The cut-off scores
found in Group 1 were examined on applicability in Group 2.
Statistical analyses were performed using the SPSS11.0 for
Windows (SPSS, Chicago, IL, USA).Results
Development of Small Fiber Neuropathy Screening
List (SFNSL) in group 1
The examination of the answers to the questions of the first
consecutive 84 patients (Group 1) revealed that seven
questions had more than 10% missing values. One question
concerned the partner and whether he/she informed the
patient about frequent leg movement at night and the
other questions concerned sexual intercourse related
questions. Therefore, we decided to remove these ques-
tions from further analyses.
The remaining remarks from the patients concerned part
I of the questionnaire. Patients indicated to find it difficult
to answer these questions because of the yes/no response
category. They were not comfortable with it because of
lack of sophistication (not detailed enough). They
frequently commented that they wanted to answer
‘sometimes’ and felt that yes was too strong and no was
also not good. For this reason, all questions in part I were
left out of the subsequent analyses. Thus, for the statistical
analyses 51 questions (25 part II and 26 part III) were used.
Subsequently, three series of discriminant analyses
were performed to find out which questions can correctlydistinguish patients with normal and abnormal TTT results.
These specific questions were selected. In the first series of
analyses the questions from Part II, were used. The number
of questions was reduced to 10. In the second series of
analyses, the same was done for the questions from Part III
of the pilot questionnaire. This resulted in 15 questions. In
the final series, the remaining questions from parts II and
III together (25 questions) were used to group patients
according to their SFN status based on their TTT scores.
This analysis showed that 83.9% of cases could be correctly
classified as having SFN using the discriminant coefficients
(Chi-square Z 38.93, p Z 0.037). Finally, we reduced the
number of questions to 21 keeping the percentage correctly
classified as having SFN at 83.9% (Chi-square Z 40.94,
p Z 0.006). This resulted in the Small Fiber Neuropathy
Screening List (SFNSL) questionnaire (see Appendix). Subse-
quently, a total scorewasmade for the SFNSLby summing the
scores of the 21 questions. It appeared that a cut-off score of
<11 (n Z 21; 25% of patients) indicated only patients with
normal TTT and a cut-off score of >48 (n Z 16; 19% of
patients) indicated only patients with abnormal TTT. In 47
patients a score range from 11 to 48was found (56%) of which
the majority had an abnormal TTT.
Reliability and validity in group 1
Exploratory factor analysis was employed to examine
content validity. Herewith the number of underlying factors
measured by the questionnaire can be determined using the
scree test. The scree test criterion clearly showed that the
SFNSL consisted of only one underlying factor.
Furthermore, construct validity of the SFNSL was
assessed. Construct validity is the extent to which the SFNSL
actually assesses what it is intended to assess. This is exam-
ined by assessing the relationship of this questionnaire with
other questionnaires. For this purpose the relationship with
the neuropathic pain scale (NPS) was examined. Compared
with patients without pain (mean SFNSL score Z 18.4,
SDZ 12.1), patientswho indicated to have pain (mean SFNSL
score Z 29.8, SD Z 15.4) scored significantly higher on
the SFNSL (tZ e2.58, pZ 0.012). Furthermore, in patients
with pain, the correlation between pain at this moment
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(p < 0.001).
Internal consistency (Cronbach’s alpha) was assessed to
find out to what extent the different questions of the SFNSL
were related with each other. The Cronbach’s alpha was
0.89. Correlations between individual items (questions 1
through 21) and the total score of the questionnaire (minus
that item) were always significant and positive. The item-
total correlations ranged from 0.25 to 0.70.
Cross-validation of the SFNSL in Group 2
The SFNSL was then completed by the following consecu-
tive 55 patients (Group 2). There were no missing values.
The cut-off scores provided by Group 1 were also useful in
Group 2. Now, 22% (n Z 12) of the patients had an SFNSL
above 48. They all had an abnormal TTT. The percentage of
patients with an SFNSL score below 11 was 25% (n Z 14).
These latter cases all had a normal TTT.
Again exploratory factor analysis showed that the SFNSL
measured one construct, since the scree test clearly
showed one factor. The Cronbach’s alpha was 0.90 and the
item-total correlations ranged from 0.29 to 0.72.
Total group
Cronbach’s alpha for the total scale was 0.90 and item-total
correlations ranged from 0.32 to 0.67. Based on TTT results,
sensitivity and specificity of the SFNSL was 100% and 31%,
respectively, when a cut-off score of 11 is used and 19% and
100%, respectively, when a cut-off score of 48 is used.
Overall, 77 patients (55.4%) had an SFNSL score between
11 and 48, of which 79.2% (n Z 61) had an abnormal TTT.
When subdividing this category into three subcategories the
TTT scores appeared to be as follows. In the patients with
an SFNSL score between 11 and 24 an abnormal TTT was
found in 81.8% (nZ 27) of the 33 cases, in 71.4% (nZ 20) of
the patients with a score between 24 and 37 (nZ 28) and in
87.5% (nZ 14) of the patients with an SFNSL score between
37 and 48 (n Z 16), respectively.
Healthy controls
All the 15 tested healthy controls had a normal TTT.
Moreover, the SFNSL scores of all of them were below 11.
Discussion
A short and easy to administer questionnaire to screen for
SFN in sarcoidosis patients was developed. The question-
naire was crossvalidated in a second group. Cut-off scores
of below 11 for certainly no SFN and above 48 for certainly
SFN were established based on TTT results. The reliability
and validity analyses revealed results that exceeded
minimum quality standards for an instrument of this kind.
Internal consistency revealed that this scale was highly
unified, a conclusion supported by content validity assess-
ment that revealed that the SFNSL measured only one
underlying factor. These results strongly argue that SFN is
a unified condition and they argue against a psychogenetic
origin of the symptoms of SFN. Therefore, we recommendthe SFNSL as a screenings instrument to assess the possible
presence of SFN in the management of patients suffering
from sarcoidosis.
The SFNSL was found to be related to the TTT and
therefore actually identifies those patients who have an
abnormal TTT. Strict TTT criteria were used to diagnose
SFN. Both MLE and MLI test results had to exceed the 99%
value of a normal population to score TTT results as
abnormal. These sharp cut-off scores were used as we
wanted a high specificity of TTT in order to be relatively
certain which patients do have SFN. Consequently, based
on the present results patients with an SFNSL score above
48 can highly likely be diagnosed as suffering from SFN. At
the same time a cut-off score for the questionnaire that
indicated patients who certainly did not have SFN was
mandatory. An SFNSL score below 11 indicated normal TTT
results in all the examined patients. Moreover, in the 15
tested healthy controls the SFNSL scores all appeared to be
less than 11 and TTT results were all normal. Consequently,
an SFNSL score below 11 seems to exclude the presence of
SFN.
A large range of patients had an SFNSL score between 11
and 48, indicating possible SFN. In this group of patients
21.4% had normal TTT and 78.6% had an abnormal TTT. We
assume that those patients with abnormal TTT results most
probably have SFN, based on the strict TTT criteria used.
Former studies have found a sensitivity of TTT ranging from
60 to 85%.9,14,27e30 Thus, patients with a symptom score
between 11 and 48 with normal TTT may still have SFN,
especially those with SFNSL scores above 37 and more
closely to 48. In those cases other tests such as skin biopsy
and QSART should be used to further analyse the presence
of SFN. Consequently, if the SFNSL is used for screening,
aiming at high sensitivity, a cut-off value of 11 appears
appropriate.
A limitation of the present study is the fact that
a golden standard for the diagnosis of SFN is lacking. We
used TTT to diagnose SFN. Reported correlations between
SFN screening methods differ.29,31,32 Consequently, the
diagnostic value and cut-off scores of the SFNSL should be
examined further in future studies, using also other clin-
ical tests that can be used to diagnose SFN, such as intra-
epidermal nerve fiber density assessment in skin biopsy,
QSART, laser evoked potentials, corneal confocal micros-
copy and cardiovascular autonomic function testing.
Another limitation is that only sarcoidosis patients
participated. Most probably, the SFNSL is also useful in
idiopathic SFN or those due to other causes. However, this
assumption has to be examined. Moreover, although the
range of the time since diagnosis was 0e35 years, it is
clear from the results that an abnormal TTT and clinical
signs of SFN were more prominent in cases with a longer
disease history. Possibly, longer duration of inflammation
results in a larger chance of small nerve damage.
However, also in patients with a short history of sarcoid-
osis SFN appeared to be present. The prevalence at
different disease durations should be established in future
prospective studies to gain more insight in the effect of it.
Patients included in this study were patients referred to
the sarcoidosis management team of our hospital. We are
a tertiary referral centre in the Netherlands for refractory
sarcoidosis patients. That means that a lot of the patients
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patient we advice a colleague in another hospital in the
Netherlands with regard to the diagnosis and management
of the patient. This implicates that we not often have
follow-up data of these patients. However, 10 patients
with a normal TTT at inclusion in the study with an SFNSL
score between 11 and 48, were followed. Seven of them
(70%) appeared to have an abnormal TTT two years later.
In our experience the neuropathy is waxing and waning in
the majority of cases. Currently, no appropriate therapy is
available. Data using anti-TNF-alpha drugs seem prom-
ising.7,33 Moreover, some patients suffering from SFN may
show increasing signs and symptoms over time.34
However, exact data on progression of SFN in sarcoid
patients are not jet available.
As SFNhas only recently gainedmore attention, exact data
on prognosis, clinical course, treatment and treatment effi-
cacy are lacking.33e37 Furthermore, the condition may be
easily missed as symptoms of autonomic dysfunctionmay not
always be recalled spontaneously by the patient.12,35 More-
over, even if reported, symptoms such as diarrhea, mictura-
tion disturbances and sweatingmay not always be recognised
as such. In this respect, recognition of SFN is important
because it may prevent extensive investigations such as
colonoscopy in the case of diarrhea or urodynamic investi-
gation in case of micturation disturbances. And finally, testsPart 1:
These questions are aimed at finding out how often you experien
1. I have painful arms
2. I suffer from palpitations
3. I have problems with my bowel movements
4. I have difficulties with urinating (either in emptying
my bladder or being able to hold my water)
5. My food does not seem to go down well
6. I suffer from muscle cramps
7. My feet and/or hands are colder than I am used to
8. I have chest pain
Part 2:
These questions are aimed at finding out how serious your co
9. I have the feeling that my food gets stuck in my throat
10. At night I throw the bedclothes off my legs
11. I have difficulties with urinating (either emptying my bladder
or being able to hold my water)
12. I have dry eyes
13. I have blurred vision
14. I feel dizzy when I get up
15. I have sudden hot flushes
16. My feet and/or hands are colder than I am used to
17. I have painful arms
18. The skin of my legs is over-sensitive
19. I have a tingling sensation in my hands (pins and needles)
20. I have a tingling sensation in my legs (pins and needles)
21. I have chest pain
Please see: http://www.ildcare.nl/index.php?idZ100 for th
ªild care foundation www.ildcare.eu.for assessment of SFNare notwidely availablewhile routinely
applied nerve conduction studies and EMG remain normal in
SFN patients.
In conclusion, the SFNSL is strongly recommended as first
screening tool for various disciplines involved in the
management of sarcoidosis patients with possible SFN, such
as pulmonologists, neurologists, rheumatologists, etc. The
SFNSL is a practical, brief and easy to assess tool in
screening for the presence of SFN. It is brief and offers the
possibility of ready use in the management and follow-up of
sarcoidosis patients with suspected SFN in clinical practice,
in epidemiological and pathophysiological research, and in
clinical trials.
Appendix:
Small fiber neuropathy screening list
Below are a number of questions about possible
complaints. Please circle the answer to each question
that is applicable to you. Please give an answer to
each question, even if you do not have any complaints
at the moment.
The aim of this questionnaire is to find out how you
experience your complaints. There are no correct or
incorrect answers. It is important that you are honest.ce the following complaints.
never/sometimes/variably/often/always
never/sometimes/variably/often/always
never/sometimes/variably/often/always
never/sometimes/variably/often/always
never/sometimes/variably/often/always
never/sometimes/variably/often/always
never/sometimes/variably/often/always
never/sometimes/variably/often/always
mplaints are.
not at all/slightly/variably/moderately/seriously
not at all/slightly/variably/moderately/seriously
not at all/slightly/variably/moderately/seriously
not at all/slightly/variably/moderately/seriously
not at all/slightly/variably/moderately/seriously
not at all/slightly/variably/moderately/seriously
not at all/slightly/variably/moderately/seriously
not at all/slightly/variably/moderately/seriously
not at all/slightly/variably/moderately/seriously
not at all/slightly/variably/moderately/seriously
not at all/slightly/variably/moderately/seriously
not at all/slightly/variably/moderately/seriously
not at all/slightly/variably/moderately/seriously
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